Sclerosis News
-
Clinical benefits of exoskeletons
Helena López; why did you decide to become a physiotherapist? Because I like dealing with people, I like helping, I like healthcare… All these reasons were leading me towards medicine, but, in that case, I would spend little time with the patient. I preferred the contact, to be more involved in their evolution. And what made me decide, specifically for the field of neurology, was ...
-
Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. ...
-
Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference
Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster ...
-
Kadimastem Expands R&D Program to Include Multiple Sclerosis
Ness Ziona, Science Park, May 18, 2022 - Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services ...
-
Gesynta Pharma`s drug candidate GS-248 granted Orphan Drug Designation in US by the FDA for the treatment of systemic sclerosis
Gesynta Pharma AB today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company's drug candidate GS-248 for the treatment of systemic sclerosis. GS-248 is currently being evaluated in a Phase II clinical trial as a treatment for Raynaud's phenomenon secondary to systemic sclerosis. Orphan Drug Designation is intended to encourage the ...
-
How Tomagatchi Hacked the Human Brain
According to an article from Nerdist, “A team of scientists from the University of Cambridge has used the ‘mini brains’ to analyze serious maladies like lateral sclerosis and even dementia. Something they were able to do thanks to stem cells from patients themselves”. Read the full story here: ...
By ni2o, Inc.
-
Qynapse Unveils its New Brand and Latest Developments in Neuroimaging AI Innovation at the 2021 RSNA Meeting in Chicago
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting, from ...
By Qynapse
-
Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available
Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital ...
-
Haymarket Medical Network Launches Rare Disease Advisor
Haymarket Medical Network today launched Rare Disease Advisor, a new digital resource for healthcare professionals (HCPs) to help them recognize, diagnose, refer and treat rare diseases. RareDiseaseAdvisor.com fills an information gap for HCPs by providing difficult to find information on rare diseases in one convenient place, enabling physicians and care teams with a comprehensive digital ...
-
Phase II update: Gesynta Pharma announces significant progress across development program for first-in-class drug candidate GS-248
Gesynta Pharma AB today announced that an IND (Investigational New Drug Application) has been submitted to the U.S. Food & Drug Administration for its oral drug candidate GS-248 in patients with systemic sclerosis. Concurrently, more than half of the patients in the ongoing Phase II study in four countries across Europe have been recruited. The study investigates the safety of GS-248 and ...
-
Remedica provided financial support to the Cyprus Multiple Sclerosis Association
In the spirit of being supportive to society, Remedica provided financial support to the Cyprus Multiple Sclerosis Association. The main purpose of the association is to help and support people with multiple sclerosis as well as their families by providing various services through its programs. The financial contribution was made on the 1st of March, at the association’s premises. Mr ...
-
Gesynta Pharma initiates Phase II study of its first-in-class drug candidate GS-248 in patients with systemic sclerosis
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and peripheral blood flow in this ...
-
Gyroscope Therapeutics and the University of Pennsylvania Announce Research Agreement to Develop Gene Therapies for Serious Eye Diseases
LONDON – Friday 18 December 2020 – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced the company has entered a sponsored research agreement with the University of Pennsylvania and the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to develop gene therapies for serious eye diseases that can lead ...
-
New Clinic in Turkey with Exoskeleton
There is an opportunity to undergo rehabilitation course with ExoAtlet for all patients who require rehabilitation from the effects of stroke, spinal cord injury, multiple sclerosis, cerebral palsy in Turkey. We have partnered with Romatem – the first and only medical center in Turkey specializing in the field of physiotherapy and rehabilitation. For more than 12 years the center have been ...
By ExoAtlet
-
Flowonix Receives FDA Approval to Market Prometra II Pump for use with Intrathecal Baclofen
Flowonix Medical, Inc. today announced United States Food and Drug Administration (FDA) approval to market the Prometra II Programmable Pump System for use with intrathecal baclofen. Flowonix introduced the Prometra II 40mL pump to the US market in November 2019, providing patients and clinicians a choice between 20 mL and 40 mL capacities when choosing an intrathecal pump delivery device. The ...
-
Brain Sentinel Announces Launch of SeizureLink, its sEMG-Based Seizure Alerting System, Available Without a Prescription
Brain Sentinel Consumer Systems, LLC (herein “Brain Sentinel”) announces the global launch of its new SeizureLink™ Alerting System at the Epilepsy Foundation’s “2018 Epilepsy Pipeline Conference”, currently being held in San Francisco, CA. Pre-ordering for the U.S. will begin in March 2018, with shipments planned to begin by mid-summer via SeizureLink.com. ...
-
Brain Sentinel’s SPEAC® System Named `Best of What’s New` for 2017 by Popular Science Magazine
Popular Science magazine has named the SPEAC® System "Best of What’s New in 2017" in the Health category. The SPEAC® System is the first FDA-cleared, non-EEG, physiological, signal-based system for seizure monitoring. "We are excited and thrilled by this award from Popular Science," said Mike Girouard, President, CEO and co-founder of Brain Sentinel, Inc. Girouard ...
-
Saneron and USF Patent Method for Umbilical Cord Blood Cell Use
Researchers at Saneron CCEL Therapeutics, Inc. of Tampa, Florida, (www.saneron-ccel.com) and the University of South Florida have received a patent relating to a method for obtaining and using umbilical cord blood cells from a donor or patient to provide neural cells for transplantation aimed at repairing a variety of neurodegenerative diseases of the brain and spinal cord, such as ...
-
Zimmerman corporate culture catches new momentum
Jordan Zimmerman and Pat Patregnani have a need... for speed, and they're taking their employees along for the ride. Patregnani, an avid cyclist, launched 'zMotion' more than five years ago, hoping to apply the company's energy and enthusiasm to a higher cause. With Zimmerman on board, they haven't hit the brakes since. Since its inception, zMotion has become a leading force within the South ...
-
PERKINELMER AND PREDICTIVE DIAGNOSTICS ANNOUNCE DISCOVERY OF BLOOD BIOMARKERS FOR ALZHEIMER’S DISEASE
Results of Joint Study Presented at the American Association for Clinical Chemistry Conference BOSTON & VACAVILLE, CALIFORNIA , April 19, 2005 – PerkinElmer Inc. (NYSE: PKI ), a leading provider of drug discovery, life science research, and analytical solutions and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation (NASDAQ: LSBC), announced ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you